You can feel secure putting your trust in Moffitt Cancer Center. Every year thousands of patients across the country travel to Florida to seek treatment at Moffitt. Our experts lead the way in cellular immunotherapy research and treatment for blood cancers, and they are pioneering new treatments like chimeric antigen receptor (CAR T), tumor infiltrating lymphocytes (TILS) and T cell receptor (TCR) therapy as well as the use of immunotherapy in solid tumors. These groundbreaking innovations in immunotherapy have had a huge impact on patient outcomes.
We now have patients, who had no other viable treatment options at the time, who are in ongoing complete remission six years later after a single infusion of CAR T cells.
What is cell therapy?
Cell therapy is a novel treatment that uses the body’s own immune system to enhance its ability to find and target cancerous cells. Moffitt offers several types of cellular immunotherapy, including chimeric antigen receptor (CAR) T-cell therapy, T-cell receptor (TCR) therapy, tumor-infiltrating lymphocytes (TIL) therapy, dendritic cell vaccine.
Moffitt has been a driving force in getting several cellular immunotherapies FDA-approved and continues to lead in expanding immunotherapy options for patients. Some FDA immunotherapy approvals include:
- Lifileucel (Amtagvi™) for the treatment of individuals with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 positive, a BRAF inhibitor with or without a MEK inhibitor.
- Zxicabtagene ciloleucel (Yescarta) for the treatment of adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy.
- Idecabtagene vicleucel (Abecma) for individuals with multiple myeloma that either hasn’t responded to or has returned after at least four different prior cancer treatments.
- Ciltacabtagene autoleucel (Carvykti) for adults with multiple myeloma that either isn’t responding to treatment or has returned after receiving at least four lines of cancer therapy.
- Pembrolizumab (Keytruda) an immune checkpoint inhibitor immunotherapy used for 16 types of cancer including certain types of triple negative breast cancer, non-small cell lung cancer, kidney cancer, cervical cancer and others
- Lisocabtagene maraleucel (Breyanzi) for the treatment of large B cell lymphoma when the first treatment has not worked or the cancer returned within a year of the first treatment; OR the first treatment has not worked or the cancer returned after the first treatment, and the patient is not eligible for hematopoietic stem cell transplantation because of medical conditions or age; OR two or more kinds of treatment have not worked or stopped working. It is also for the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma when two or more kinds of treatment have not worked or stopped working.
A team of experts dedicated to you
Not only is Moffitt a world-leader in developing and using immunotherapies, we are also the first center in the country to develop a dedicated Immune Cell Therapy (ICE-T) unit. The state-of-the-art unit gives patients and caregivers a better treatment experience, including a team of experts entirely dedicated to cellular immunotherapy treatment, personally guiding patients every step of the way. This means throughout your entire treatment you will come to the same place - and see the same team - from start to finish.
Find a Doctor
Who can be treated with immunotherapy?
Patients with certain types of cancers who have not had success with other lines of therapy may be candidates for immunotherapy.
Those with the following types of cancers can be treated with immunotherapy at Moffitt
Request an AppointmentWhat do our patients and providers think about immunotherapy?
I'm in remission, I feel good, I got my appetite back and I've done very well. I would not be here today if it wasn't for Moffitt.
Charles,
Lung Cancer Survivor
We have seen the most incredible outcomes with this approach. We're now able to cure more patients than ever before and its really changed the way we treat a lot of blood cancers.
Dr. Ciara Freeman
Department of Blood and Marrow Transplant and Cellular Immunotherapy
This breakthrough [TIL Therapy] is the next generation of cellular immunotherapy and provides a much-needed option for metastatic melanoma patients.
Amod Sarnaik
Department of Cutaneous Oncology
I got a phone call from my oncologist and he said ‘Just go to Tampa, you’re going to go Moffitt’ and that’s when I was introduced to immunotherapy. Once I tried the CAR T therapy, I came out a winner.
Dimas
Non-Hodgkin Lymphoma Survivor